Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement

Executive Summary

Biogen's strategy to meet its Amevive (alefacept) 2003 sales target includes increasing the physician referral rate and shortening the time needed for patients to secure reimbursement

You may also be interested in...



Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches

Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain

Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches

Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain

Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution

Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive

Related Content

UsernamePublicRestriction

Register

PS042182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel